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Summary A new method for more timely monitoring of cancer patient survival was employed to assess progress in 5-year survival of breast
cancer patients in Saarland, Germany, between 1980-84 and 1990-94. Five-year relative survival gradually increased from 68.8% to 73.5%.
Improvements were most pronounced among age groups 50-59 and 60-69. The latter had the highest 5-year relative survival (77.1%) in
1990-94.
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Mortality from breast cancer has been increasing over the last few
decades in most European countries. but more recently rates have
levelled offor even started to decline in some countries. including
the Federal Republic of Germany (Hermon and Beral. 1996). It
has been suggested that the recent change in mortality trends may
be due to increased survival resulting from improved management
and treatment of women with breast cancer (Beral et al. 1995:
Baum. 1995). A slight improvement or no change in 5-year rela-
tive survival for patients diagnosed in 1983-85 compared with
patients diagnosed in 1978-80 was seen for various European
countries in the EUROCARE study (Berrino et al. 1995). but more
recent population-based survival data are very sparse.
In this paper. we report on recent trends of survival of breast
cancer in Saarland. Germany. A new method of monitoring
survival was employed that allows more timely detection ofrecent
trends (Brenner and Gefeller. 1996).
MATERIAL AND METHODS
This analysis is based on data of the population-based cancer
registry of Saarland. Germany. Saarland is a state in Western
Germany with a population of about one million inhabitants. The
Saarland cancer registry was founded in the 1960s. The main
sources ofregistration are the records from hospital inpatients and
outpatients, pathology andradiotherapy departments. medical prac-
titioners and death certificates. Multiple notifications on the same
patient are identified through a sophisticated computer-assisted
record linkage that includes search strategies based on various
combinations of patients' names, birth dates, sex and addresses.
Questionable links are resolved manually. Mortality follow-up is
ensured by an analogous record linkage of registry data with
Saarland's official mortality statistics (migration ofcancer patients
across state borders is negligible in this population).
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The cancer registry of Saarland is the only population-based
cancerregistry in the Western part ofGermany that met the quality
and completeness criteria for inclusion in all of the last four
volumes of Cancer Incidence in Five Continents edited by the
International Agency for Research on Cancer (Waterhouse et al.
1982: Muir et al. 1988: Parkin et al. 1992. 1997). More than 90%c
of breast cancers were verified histologically, and the proportion
of cases notified by death certificates only has been below 5%
since the early 1970s. Using a three-source (notifications from
clinicians, pathologists and death certificates) capture-recapture
approach. completeness of the Saarland cancer registry has
recently been estimated to have been above 95% since the early
1970s (Brenner et al. 1994).
The present analysis includes women with a first diagnosis of
breast cancer (ICD-9 position 174) below age 80 between 1975
and 1994 who were followed with respect to vital status by 31
December 1994. Patients who were notified to the cancer registry
by death certificate only were excluded from the analysis.
Analysis of survival was performed using a new approach.
denoted 'period monitoring', that allows more timely detection of
changes in survival rates. The approach is described in detail else-
where (Brenner and Gefeller, 1996). Briefly. the principle is as
follows: cumulative survival rates are calculated by calendar
periods of observation rather than by cohorts of patients defined
by common calender periods of diagnosis. For example. using 31
December. 1994 as closing date offollow-up, a recent estimate of
5-year cumulative survival for the period 1990-94 is obtained by
exclusive consideration ofthe survival experience (during the first
5 years following diagnosis) within that period of patients diag-
nosed in 1985-94. By contrast, the most recent estimate of 5-year
survival using traditional 'cohort monitoring' of survival would
reflect the survival experience during 1985-94 of patients diag-
nosed in 1985-89. If survival rates are constant over time. cohort
monitoring and period monitoring yield identical results. It has
been shown, however, that the period monitoring approach enables
much more timely detection of changes in long-term cumulative
survival rates than traditional cohort monitoring of sur ival.
In this study. absolute and relative 5-year cumulative survival
rates are estimated by the modified life table method described by
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Figure 1 Develpments in 5-year relative survival of breast cancer patients by age in Saarland, Gerrnany, between 1980-84 and 1990-94. All estimates are
derived by the pernod-montonng approach (Brenner and Gefeller, 1996)
Brenner and Gefeller (1996) for calendar periods 1980-84.
1985-89 and 1990-94 to disclose recent trends in survival.
Relative survival rates quantify the ratio ofobserved survival rates
to the expected survival rates (Ederer et al. 1961). Expected
survival rates were derived from period life tables of the Western
part of Germany for the corresponding years. Greenwood's
formula was used to calculate 95% confidence intervals of cumu-
lative survival estimates (Greenwood. 1926). Changes in 5-year
relative survival over time were tested for statistical significance
using a chi-square test for linear trend between periods (Parmar
and Machin. 1995).
RESULTS
Overall. 9766 women below age 80 with a first diagnosis ofbreast
cancer were notified to the cancer registry ofSaarland in 1975-94.
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Table 1 Absolute and relative cumulative 5-year survival estimates (950o
confidence intervals) of breast cancer patients by age and penod of
diagnosis. All estimates are derived by the period monitoring approach
(Brenner and Gefeller. 1996); Saarland. Germany 1980-94
Calendar period
Type of
estimate Age 1980-84 1985-89 1990-94
Absolute
0-49 72.8 (68.9-76.6) 72.4 (68.8-76.1) 74.9 (71.3-78.5)
50-59 61.7 (57.7-65.7) 65.6 (61.5-69.7) 68.1 (64.3-71.9)
60-69 65.7 (61.8-69.7) 66.2 (62.5-69.9) 72.5 (69.2-75.7)
70-79 54.1 (49.9-58.4) 58.6 (54.8-62.5) 58.5 (54.6-62.4)
0-79 63.6 (61.6-65.7) 65.5 (63.6-67.5) 68.6 (66.8-70.4)
Relative
0-49 73.5 (69.7-77.4) 73.1 (69.5-76.8) 75.6 (72.0-79.2)
50-59 63.6 (59.5-67.7) 67.4 (63.2-71.6) 69.7 (65.8-73.6)
60-69 70.9 (66.7-75.2) 70.6 (66.7-74.6) 77.1 (73.7-0.6)
70-79 67.7 (62.4-73.1) 71.8 (67.1-76.5) 70.6 (65.8-75.3)
0-79 68.8 (66.7-71.0) 70.7 (68.6-72.8) 73.5 (71.5-75.4)
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Figure 2 Most recent cohort and period estimates of 5-year cumulative
relative survival of breast cancer patients in Saarland. Germany. that could be
obtained by the end of periods 1980-t84. 1985-89 and 1990-94. *. Cohort:
LI penod
After exclusion of 243 women notified to the cancer registrx by
death certificate onlx. 9523 women remained for the analvsis.
Table 1 shows the development of absolute and relative 5-xear
survival rates betxeen 1980-84 and 1990-94 by age. In all age
groups combined absolute sunrixal rates gradually improxed from
63.6%s in calendar period 1980-84 to 68.6%- in calendar period
1990-94 (P-value for linear trend = 0.0002). This improvement was
not due to reduced mortality from other causes. as a similar improxe-
ment x as seen in relatixe sunvix-al estimates. Improvement of
surnixal Aas most pronounced forage group 50-59 betx een calendar
penods 1980-84 and 1985-89. and for age group 60-69 between
calendar periods 198589 and 1990-94. In the latter age group. rela-
tixe cumulative sunrial exceeded 77%i in 1990-94. Throughout the
periods of inxestigation. absolute 5-X-ear suvival was lowest in age
group 70-79. and relative 5-sear survixal was lowest in age group
50-59. despite major improvement in both age groups between
calendar periods 1980-84 and 1985-89. There was only a minor
improvement in prognosis among patients below- are 50.
A more comprehensive picture of development of relative
sunrival over time is aixen in Figure 1. which depicts survival
functions bv age at diagnosis for calendar periods 1980-84 and
1990-94. Whereas similar improvements in prognosis during the
first Xears following diagnosis are seen in all age groups. the more
faxourable dex elopment of sun ix al in age groups 50-59 and
60-69 than in the other age groups mainly exolved in later Xears of
follow--up.
Finally. the period estimates of 5-xear cumulative relative
sun-ix al for all age groups combined for periods 1980-84.
1985-89 and 1990-94 are compared xith the corresponding tradi-
tional -cohort estimates' that might have been obtained bv the end
ofthose periods (pertaining to patients diagnosed in the 5 calendar
years before the periods under investigation). This comparison.
depicted in Figure 2. reveals xerx similar estimates by the end of
the 1980-84 period. suggesting that there were no major chances
in sunrixal before that date. Both approaches showx considerable
improvement in lateryears. but the cohort approach lags behind in
terms ofrexealing! the onset and extent of the improvement.
DISCUSSION
This paper discloses recent advances in breast cancer sunrixal in
Saarland. Germany. These advances. which were most prominent
in patients aged 50-69 years at diagnosis. are not explained by the
general increase in life expectancy. as relative sunix al rates
increased almost as much as absolute surnixal rates.
The relative 5-xear sunixal estimate of 73.5% for the period
1990-94 is considerably higher than the most recent estimate of
68% that has prex iously been reported for breast cancer patients in
Saarland diagnosed in 1983-85 (Berrino et al. 1995). Apart from
some variation in the are groups inxolxed (patients abox e 80 were
included in the EUROCARE study). this difference is likelv to
reflect the more recent data available for the current analysis as
well as the different analytic approach that allows more timely
detection of recent changes. It should be noted. however. that the
period approach. which provides the most timely estimates of
sun-ix al experience ax ailable to date. may still underestimate
sun-ival of the most recently diagnosed cohorts of patients. which
xill onlx be known after these cohorts have been obsenved over a
minimum of5 years.
In theorx. improvements in sunrixal may be explained by two
major mechanisms: firstly. improx ed sun-ix-al as a result of earlier
diagnosis: and. secondly. improxed surn-ial as a result ofadxance-
ments in therapy.
Improvement in sunix al resulting from earlier diagnosis miaht
be related to progress in breast cancer screening. In Germany. a
yearlv screening examination including palpation and instruction
for breast self-examination has been offered for women above age
30 throughout the period of investigation. Although mammog-
raphy is not a routine component ofthe screening programme. it is
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According to national statistics. yearly participation rates
remained rather constant between 30% and 35% of eligible
women until 1991. Since then, participation rates gradually
increased to 44% in 1994 (Federal Ministry of Youth, Family.
Women and Health, 1997). Unfortunately, information on stage at
diagnosis was only available in the registry records of 71% of
women diagnosed with breast cancer below age 80 in Saarland in
1975-94. which makes analyses of time trends difficult.
Nevertheless. there appeared to be some trend towards earlier
diagnosis: among patients with known stage at diagnosis. the
proportion with localized cancer increased from 39% in patients
diagnosed in 1975-84 to 42% in patients diagnosed in 1985-94.
Clinical trials have indicated considerable improvement in
prognosis in patients above age 50 who received adjuvant tamox-
ifen therapy (Early Breast Cancer Trialist's Collaborative Group.
1992). Detailed data on treatment are not available in the Saarland
cancer registry. Given inclusion oftamoxifen therapy in treatment
recommendations in Germany in recent years, it appears plausible,
however, that improvements in survival may at least partly be due
to increased use of this therapy. Nevertheless, other factors, such
as a change in the natural history ofthe disease, might also play a
role (Joensuu and Toikkanen. 1991).
Regardless of their origin. the most recent improvements in
survival disclosed in this paper should help to prevent clinicians
and their patients from being discouraged by outdated overly
pessimistic survival statistics. Despite considerable improvement
however, our up-to-date estimates of 5-year relative survival in
Germany still lag behind those observed for patients diagnosed in
othercountries, such as Switzerland. Finland and the United States
(McIntosh. 1992: Berrino et al. 1995). This suggests that further
improvement should be possible.
REFERENCES
Baum M (1995) Screening for breast cancer. time to think - and stop" letter).
Lancet 346: 436-437
O Cancer Research Camnpaign 1998
Improvedsurvival ofbreastcancerpatients 697
Beral V. Hermon C. Reeves G and Peto R 1995 Sudden fall in breast cancer death
rates in England and Wales (letter). Lancet345: 1642-1643
Berrino F. Sant M. Verdecchia A. Capocaccia R. Hakulinen T and Este-ve J 1995)
Sur-ival ofCancer Patients in Europe - The Eurocare Stud%-. Scientific
Publications No. 132. LARC: Lvon
Brenner H and Gefeller 0 1996) An alternative approach to monitoring cancer
patient survival. Cancer78: 2004-2010
Brenner HL Slegnaier C and Ziegler H 1994) Estimating completeness ofcancer
registration in Saarland/Germany with capture-recapture methods. EurJ
Cancer30A: 1659-1663
Early Breast Cancer Trialist's Collaborative Group) 1992) Systematic treatment of
early breast cancer by hormonal. cytotoxic. or immune therapy. Lancet339:
1-15and71-85
Ederer F. Axtell LM and Cutler SJ 1961) The relatise sumival rate: a staistical
methodologk.Natl Cancer Inst Monogr6: 101-121
Federal Ministrv ofYouth. Famnily. Women and Health )1997) Data ofthe Health
Care System [in German]. Nomos: Baden-Baden
Greenwood M 1926) The errors ofsampling ofthe survivorship tables. In Reports
on Public Health andMedical Subjects. No. 33. Appendix I. His Majesty's
Stationery Office: London.
Hermon C and Beral V 1996) Breast cancer mortality rates are levelling offor
beginning to decline in many western countries: analysis oftime trends. age-
cohort and age-period models ofbreast cancer mortalitN in 20 countries.
BrJ Cancer 73: 955-960
Joensuu H and Toikkanen S ( 1991 ) Comparison ofbreast carcinomas diagnosed in
the 1980s with those diagnosed in the 1940s to 1960s. BrMedJ303: 155-158
McIntosh H 1992) 1971-1991: Diagnosis and treatment advances improve survival.
I Vatl CancerInst 83: 234-236
Muir C. Waterhouse J. Mack T. Powell J and Whelan S (eds) ( 1988) Cancer
Incidence in Five Continents. Vol. V. Scientific Publications No. 88. LARC:
Lyon
Parkin DM. Muir CS. Whelan SL Gao Y-T. Ferlay J and Pow-ell J (eds) ( 1992)
CancerIncidence in Five Continents. Vol. VI. Scientific Publications No. 120.
IARC: Lyon
Parkin DM. Whelan SL Ferlay J. Raymond L and Young J (eds) 1997) Cancer
Incidence in Five Continents. Vol. VI. Scientific Publications No. 143. LARC:
Lyon
Parmar MKB. Machin D ( 1995) SurvivalAnalysis. A PracticalApproach. John
Wiley & Sons: Chichester
Waterhouse J. Muir C. Shanmugaratnam K and Powell J )eds) 1982) Cancer
Incidence in Five Continents. Vol. IV. Scientific Publications No. 42. LARC:
Lyon
British Journal of Cancer (1998) 78(5), 694-697